Parkinson DiseaseNCT05820425
Local Fields Potentientals of the Subthalamic Nucleus in Patients With Parkinson's Disease
An observational study of Parkinson Disease, run by University Hospital, Grenoble at 1 site in France.
Trial summary
Neuropsychiatric fluctuations are frequent and debilitating non-motor disorders in Parkinson's disease. Subthalamic stimulation is an effective treatment for motor and non-motor neuropsychiatric fluctuations in Parkinson's disease, which has also allowed to better characterize the electrophysiological activity of the… Read more about this study
- Who is it for?
- Ages 30 to 75 years
- Conditions the study is for
- Parkinson Disease
- What is being tested?
- LFP and EEG recording
- How many people
- 12 participants
- Where
- 1 siteFrance
- Study dates
- 7 Apr 2023to Feb 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: PD patients with motor and non motor fluctuations, operated within the last 10 days for STN stimulation (PERCEPT implant)
Who may be able to join
- Age between 30 and 75 years
- Diagnosis of Parkinson's disease with fluctuations and/or dyskinesias
- Ability to collaborate and fill a questionnaire in the OFF state condition (this criterion will be assessed based on the results of the preoperative screening to retain indication for STN stimulation, which takes place whenever a PD patient has to undergo DBS surgery)
- Surgery for bilateral STN stimulation with a Percept® (Medtronic) in the last 10 days
- Absence of dementia (defined as MoCA score > 24)
Who cannot join
- Active psychosis
- Patients unable to provide an informed consent or under gardianship
- Patients under judicial supervision or deprived of liberty
- Pregnancy and breastfeeding
Trial locations and contacts
1 site in 1 country.
France1 site, 1 recruiting
- Recruiting
CHU Grenoble Alpes
Grenoble, 38043
Anna Castrioto, +33476769452, acastrioto@chu-grenoble.fr
Pierre PELISSIER, +33476769459, ppelissier@chu-grenoble.fr
About this study
Official title: Local Fields Potentials of the Subthalamic Nucleus in Patients With Parkinson's Disease and Neuropsychiatric Fluctuations
Neuropsychiatric fluctuations are frequent and debilitating non-motor disorders in Parkinson's disease. Subthalamic stimulation is an effective treatment for motor and non-motor neuropsychiatric fluctuations in Parkinson's disease, which has also allowed to better characterize the electrophysiological activity of the subthalamic nucleus in patients with Parkinson's disease. Numerous studies have been carried out on electrophysiological activity correlated with motor disorders, showing that akinesia is correlated with an abnormal synchronization in the beta frequency band (13-30Hz) in the dorsal motor part of the subnucleus. thalamic. This abnormal synchronization is reduced when the akinesia improves with dopaminergic treatment. On the cognitive-behavioural non-motor side, electrophysiological studies are less numerous, but suggest an involvement of the subthalamic nucleus (with an abnormal synchronization in the lower frequency bands). Currently, the electrophysiological correlates of neuropsychiatric fluctuations are unknown. In addition, all studies on electrophysiological activity are carried out immediately after the intervention, and before the implantation of the pacemaker. It is unknown whether the electrophysiological correlates of motor and non-motor fluctuations change following their transient improvement observed in the setting of chronic stimulation of the subthalamic nucleus and chronic reduction of dopaminergic treatment. The new PERCEPT stimulators (Medtronic) available on the market make it possible to record long-term electrophysiological activity for the first time. With this study we want to define the electrophysiological markers of neuropsychiatric fluctuations and their change over time.
Read the detailed description
In PD several studies have shown an abnormal synchronized activity in the beta band (13-30 Hz) in the motor dorsal STN, which correlates with bradykinesia. This abnormal activity is decreased by dopaminergic treatment and movement. In contrast, higher alpha activity is concentrated in the ventromedial part of the nucleus. Anatomically, it has been shown that the motor dorsal subthalamic nucleus is connected with the motor frontal cortex, whereas its non-motor ventral part is connected to the premotor and the prefrontal cortex.
More recently, an increasing attention has been focused on the key role of the STN in emotion and cognition in Parkinson's disease. Neuropsychiatric symptoms indeed represent a real burden for patients with PD and their caregivers. Patients might experience fatigue, depressive symptoms, anxiety, apathy, impulse control disorders, punding, hallucinations, and impaired cognition. Moreover, neuropsychiatric symptoms might fluctuate along the day. During the off state, patients might present with fatigue, lack of energy and motivation, low mood and slowness of thought, whereas during the on state they experience a sensation of well-being, high motivation, logorrhoea with easy flow of ideas, and good attention span and liveliness. Little is known about the electrophysiological correlates of such neuropsychiatric symptoms. An increase in the background activity and a reduced oscillatory activity in the alpha spectrum was observed in the ventral part of the right STN after vocal emotional stimuli. A change in the oscillatory activity in the alpha spectrum of the STN has been recorded after visual emotional stimuli. A theta activity in the ventral region of the STN has been recorded in PD patients with impulse control disorders while on medication.
Recently, a new tool, the neuropsychiatric fluctuations scale, has been developed. This scale, contrary to the other scales measuring the non-motor fluctuations, which are mainly retrospective, allows to measure the neuropsychiatric state of the patient at the very moment of the test. This is a critical advantage as patients can be anosognosic of their fluctuations. The neuropsychiatric fluctuations scale allows measuring the neuropsychiatric state of the patient "in real time", just as the MDS UPDRS assesses the motor condition.
At present, the electrophysiological marker of neuropsychiatric fluctuations in PD is unknown. Moreover, all electrophysiological data on STN activity comes from the postoperative phase and no data are available on their evolution over time.
The PERCEPT (Medtronic) allows to record STN activity not only in the immediate postoperative phase, but also in the medium and long-term follow-up, providing an excellent tool to investigate the electrophysiological activity of the subthalamic nucleus, and its changes over time.
In addition, while there are studies on the electrophysiological correlates of motor activity in PD, no studies are available on the change of this activity in the same patient after long follow-up. It is unknown whether the electrophysiological markers of motor and neuropsychiatric fluctuations change over time, together with the improvement of fluctuations induced by chronic stimulation and reduction of dopaminergic medication. From a clinical point of view, a motor and neuropsychiatric desensitization to levodopa has been shown in PD patients treated with chronic STN stimulation. Although relatively unknown and understudied, levodopa desensitization carries significant consequence in PD, such as malignant stimulation withdrawal syndrome. To determine how the electrophysiological markers of the OFF and the ON states change over time in the same patient not only will help to elucidate the mechanisms underlying this desensitization, but it will be also crucial for implementing algorithms for adaptive stimulation.
The purpose of our study is to record the STN activity in PD patients treated with STN stimulation during neuropsychiatric and motor fluctuations and their changes over time.
RESEARCH HYPOTHESIS AND EXPECTED RESULTS Our hypothesis is that neuropsychiatric fluctuations are associated with a change in the low-frequencies band activity in the ventral region of the STN, and that motor fluctuations are associated with changes in the beta band activity in the dorsal motor region of the STN. We expect a reduction of these abnormal activities over time, associated with the reduction of fluctuations.
Great efforts are to date made in order to create an adaptive stimulation, characterized by a real-time adaptation of parameters of stimulation to the fluctuations of the patient state. Adaptive stimulation would be more efficient than the current continuous stimulation system. Results of this study will allow to better understanding the pathophysiological basis of neuropsychiatric and motor fluctuation, and moreover to implement algorithms for create an adaptive stimulation.
- Conditions
- Parkinson Disease
- Being tested
- LFP and EEG recording
- Keywords
- Local Field Potentials, Neuropsychiatric Fluctuations Scale, Subthalamic nucleus stimulation
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LFP and EEG recordingOther
STN LFP and EEG recording during the OFF and ON medication condition
| Study group | Role | What they receive |
|---|---|---|
| Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS | Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS, using PERCEPT device (Medtronic) Receives: Other: LFP and EEG recording |
What is being measured
The primary outcome is the main question the study is designed to answer.
The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON
Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.
Measured: in the 10 days following surgery
The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON
Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.
Measured: at 3 months after surgery
The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON
Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.
Measured: at 1 year after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Apr 2023
- Study start7 Apr 2023
- Primary completionFeb 2025 (estimated)
- Study completionFeb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- More trials run by University Hospital, GrenobleThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Grenoble
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Anna Castrioto, MD, PhD, Principal investigator, CHU Grenoble Alpes
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05820425
- Sponsor's protocol ID
- 38RC21.0394
- Other IDs
- 2022-A00004-39
- Status last verified
- May 2024
- First submitted
- 6 Mar 2023
- Last updated
- 3 Jun 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Local Fields Potentials of the Subthalamic Nucleus in Patients With Parkinson's Disease and Neuropsychiatric Fluctuations
- ClinicalTrials.gov ID
- NCT05820425
- Acronym / sponsor ID
- 38RC21.0394
- Conditions
- Parkinson Disease
- Keywords
- Local Field Potentials, Neuropsychiatric Fluctuations Scale, Subthalamic nucleus stimulation
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- University Hospital, GrenobleUniversity, hospital or other
- Study start
- 7 Apr 2023 (actual)
- Primary completion
- Feb 2025 (estimated)
- Study completion
- Feb 2026 (estimated)
- First posted
- 19 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Neuropsychiatric fluctuations are frequent and debilitating non-motor disorders in Parkinson's disease. Subthalamic stimulation is an effective treatment for motor and non-motor neuropsychiatric fluctuations in Parkinson's disease, which has also allowed to better characterize the electrophysiological activity of the subthalamic nucleus in patients with Parkinson's disease. Numerous studies have been carried out on electrophysiological activity correlated with motor disorders, showing that akinesia is correlated with an abnormal synchronization in the beta frequency band (13-30Hz) in the dorsal motor part of the subnucleus. thalamic. This abnormal synchronization is reduced when the akinesia improves with dopaminergic treatment. On the cognitive-behavioural non-motor side, electrophysiological studies are less numerous, but suggest an involvement of the subthalamic nucleus (with an abnormal synchronization in the lower frequency bands). Currently, the electrophysiological correlates of neuropsychiatric fluctuations are unknown. In addition, all studies on electrophysiological activity are carried out immediately after the intervention, and before the implantation of the pacemaker. It is unknown whether the electrophysiological correlates of motor and non-motor fluctuations change following their transient improvement observed in the setting of chronic stimulation of the subthalamic nucleus and chronic reduction of dopaminergic treatment. The new PERCEPT stimulators (Medtronic) available on the market make it possible to record long-term electrophysiological activity for the first time. With this study we want to define the electrophysiological markers of neuropsychiatric fluctuations and their change over time.
Detailed description
In PD several studies have shown an abnormal synchronized activity in the beta band (13-30 Hz) in the motor dorsal STN, which correlates with bradykinesia. This abnormal activity is decreased by dopaminergic treatment and movement. In contrast, higher alpha activity is concentrated in the ventromedial part of the nucleus. Anatomically, it has been shown that the motor dorsal subthalamic nucleus is connected with the motor frontal cortex, whereas its non-motor ventral part is connected to the premotor and the prefrontal cortex.
More recently, an increasing attention has been focused on the key role of the STN in emotion and cognition in Parkinson's disease. Neuropsychiatric symptoms indeed represent a real burden for patients with PD and their caregivers. Patients might experience fatigue, depressive symptoms, anxiety, apathy, impulse control disorders, punding, hallucinations, and impaired cognition. Moreover, neuropsychiatric symptoms might fluctuate along the day. During the off state, patients might present with fatigue, lack of energy and motivation, low mood and slowness of thought, whereas during the on state they experience a sensation of well-being, high motivation, logorrhoea with easy flow of ideas, and good attention span and liveliness. Little is known about the electrophysiological correlates of such neuropsychiatric symptoms. An increase in the background activity and a reduced oscillatory activity in the alpha spectrum was observed in the ventral part of the right STN after vocal emotional stimuli. A change in the oscillatory activity in the alpha spectrum of the STN has been recorded after visual emotional stimuli. A theta activity in the ventral region of the STN has been recorded in PD patients with impulse control disorders while on medication.
Recently, a new tool, the neuropsychiatric fluctuations scale, has been developed. This scale, contrary to the other scales measuring the non-motor fluctuations, which are mainly retrospective, allows to measure the neuropsychiatric state of the patient at the very moment of the test. This is a critical advantage as patients can be anosognosic of their fluctuations. The neuropsychiatric fluctuations scale allows measuring the neuropsychiatric state of the patient "in real time", just as the MDS UPDRS assesses the motor condition.
At present, the electrophysiological marker of neuropsychiatric fluctuations in PD is unknown. Moreover, all electrophysiological data on STN activity comes from the postoperative phase and no data are available on their evolution over time.
The PERCEPT (Medtronic) allows to record STN activity not only in the immediate postoperative phase, but also in the medium and long-term follow-up, providing an excellent tool to investigate the electrophysiological activity of the subthalamic nucleus, and its changes over time.
In addition, while there are studies on the electrophysiological correlates of motor activity in PD, no studies are available on the change of this activity in the same patient after long follow-up. It is unknown whether the electrophysiological markers of motor and neuropsychiatric fluctuations change over time, together with the improvement of fluctuations induced by chronic stimulation and reduction of dopaminergic medication. From a clinical point of view, a motor and neuropsychiatric desensitization to levodopa has been shown in PD patients treated with chronic STN stimulation. Although relatively unknown and understudied, levodopa desensitization carries significant consequence in PD, such as malignant stimulation withdrawal syndrome. To determine how the electrophysiological markers of the OFF and the ON states change over time in the same patient not only will help to elucidate the mechanisms underlying this desensitization, but it will be also crucial for implementing algorithms for adaptive stimulation.
The purpose of our study is to record the STN activity in PD patients treated with STN stimulation during neuropsychiatric and motor fluctuations and their changes over time.
RESEARCH HYPOTHESIS AND EXPECTED RESULTS Our hypothesis is that neuropsychiatric fluctuations are associated with a change in the low-frequencies band activity in the ventral region of the STN, and that motor fluctuations are associated with changes in the beta band activity in the dorsal motor region of the STN. We expect a reduction of these abnormal activities over time, associated with the reduction of fluctuations.
Great efforts are to date made in order to create an adaptive stimulation, characterized by a real-time adaptation of parameters of stimulation to the fluctuations of the patient state. Adaptive stimulation would be more efficient than the current continuous stimulation system. Results of this study will allow to better understanding the pathophysiological basis of neuropsychiatric and motor fluctuation, and moreover to implement algorithms for create an adaptive stimulation.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS | – | Other: LFP and EEG recordingPatients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS, using PERCEPT device (Medtronic) |
Who may qualify
- Ages
- 30 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- PD patients with motor and non motor fluctuations, operated within the last 10 days for STN stimulation (PERCEPT implant)
Key inclusion criteria (5 listed)
- Age between 30 and 75 years
- Diagnosis of Parkinson's disease with fluctuations and/or dyskinesias
- Ability to collaborate and fill a questionnaire in the OFF state condition (this criterion will be assessed based on the results of the preoperative screening to retain indication for STN stimulation, which takes place whenever a PD patient has to undergo DBS surgery)
- Surgery for bilateral STN stimulation with a Percept® (Medtronic) in the last 10 days
- Absence of dementia (defined as MoCA score > 24)
Key exclusion criteria (4 listed)
- Active psychosis
- Patients unable to provide an informed consent or under gardianship
- Patients under judicial supervision or deprived of liberty
- Pregnancy and breastfeeding
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LFP and EEG recordingSTN LFP and EEG recording during the OFF and ON medication condition | Other | Patients with Parkinson's disease with fluctuations and/or dyskinesias treated by STN DBS |
Primary outcome
The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON
Time frame: in the 10 days following surgery
Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.
The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON
Time frame: at 3 months after surgery
Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.
The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON
Time frame: at 1 year after surgery
Correlation will be performed within a general mixed effect model approach. The dependent variable will be the power spectral density (PSD, expressed as logpower (µV^2)) of the subthalamic nucleus local field potentials estimated with the Welch method. The independant variable will be measured using the neuropsychiatric fluctuations scale score.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jun 2024.
- Individual participant dataSharing planned: No
Related trials for Parkinson Disease
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Enrolling by invitationObservational study
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes
PARKINSON DISEASE (Disorder), Atypical Parkinsonism
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anna Castrioto, MD, PhD principal investigator
CHU Grenoble Alpes
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Parkinson Disease, run by University Hospital, Grenoble at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 3 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Pierre Pelissier, MsC (4 76 76 94 59 ext. +33, ppelissier@chu-grenoble.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The LFPs recordings from the STN correlating with the neuropsychiatric OFF and ON (time frame: in the 10 days following surgery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2024.